Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genetron Holdings Ltd.
Headquarters: Beijing, China
Website: https://www.genetronhealth.co...
Year Founded: 2013
Status: Private
BioCentury | Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
BioCentury | Aug 26, 2022
Finance
U.S., China audit deal puts fall inspections in spotlight
SEC says agreement needs to be tested in practice before determining compliance by year-end
BioCentury | Mar 16, 2022
Deals
March 15 Quick Takes: Blackstone backs Sanofi’s multiple myeloma trial
Plus: Keytruda, Lynparza combo misses, pandemic antiviral initiative launches and updates from Eisai, Biogen and more
BioCentury | Jul 31, 2021
Finance
What’s next for China’s biopharmas after a roller-coaster week
Volatile week underscores why U.S.-listed China companies should prepare for greater transparency and consider capital markets contingency plans
BioCentury | Jul 27, 2021
Finance
China’s market jitters clip biopharma shares
Bellwethers tumble, biotech ETFs down 7% after Beijing’s latest regulatory move
BioCentury | Jan 7, 2021
Deals
Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more
Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed
BioCentury | Oct 8, 2020
Product Development
Mapping opportunities for China’s early cancer detection boom
How Chinese companies developing liquid biopsies for cancer are approaching the potentially massive market
BioCentury | Oct 2, 2020
Regulation
Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more
Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to
BioCentury | Aug 15, 2020
Finance
As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington
$383M deal set against backdrop of White House, Senate push to tighten auditing rules
BioCentury | Jun 20, 2020
Finance
Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum
Beijing-based Genetron debuts with $1.4B valuation as quartet of biotechs price offerings
Items per page:
1 - 10 of 18